Avalo Therapeutics Engages in Key Investor Conferences
Avalo Therapeutics, Inc. (NASDAQ: AVTX), a prominent clinical-stage biotech firm dedicated to treating immune dysregulation, is gearing up to take part in important investor conferences this March. Management will highlight the company's innovative approaches and ongoing projects aimed at addressing serious health conditions.
Upcoming Conferences
The company will participate in two key events that present unique opportunities for discussion and networking.
TD Cowen 45th Annual Health Care Conference
Avalo Therapeutics will present at the TD Cowen 45th Annual Health Care Conference on March 3, 2025. This event will provide an excellent platform for the company to share its corporate vision and developments in treating immune-related conditions at 3:10 PM ET.
Leerink Partners Global Healthcare Conference
Following this, Avalo will also attend the Leerink Partners Global Healthcare Conference on March 12, 2025. This event will focus on one-on-one and small group meetings, allowing for in-depth conversations and personalized insights into Avalo's ongoing innovations.
Accessing Live Updates
For those interested in following the presentations, live webcasts, along with recordings when available, can be accessed through the "News / Events" section in the Investors area of the Avalo Therapeutics website. The archived webcasts will be accessible for at least 30 days post-event, ensuring that both investors and interested parties can catch up on the discussions at their convenience.
About Avalo Therapeutics
Avalo Therapeutics remains committed to advancing therapies for immune dysregulation. Their primary asset, AVTX-009, is an innovative monoclonal antibody targeting interleukin-1? (IL-1?), which plays a significant role in various inflammatory diseases. Beyond AVTX-009, Avalo is also developing two additional candidates: quisovalimab, an anti-LIGHT monoclonal antibody, and AVTX-008, a BTLA agonist fusion protein.
The Science Behind AVTX-009
AVTX-009 is a humanized monoclonal antibody that effectively binds to IL-1?, reducing its inflammatory activity. Dysregulation of IL-1? is a crucial factor in many autoimmune responses, and its inhibition could lead to significant improvements in conditions such as hidradenitis suppurativa, as well as other inflammatory diseases related to dermatology, gastroenterology, and rheumatology.
Connect with Avalo Therapeutics
For media inquiries or further information, Christopher Sullivan, the CFO of Avalo Therapeutics, is available at 410-803-6793 or via email at ir@avalotx.com. Additionally, for investor relations, Lauren Glaser from Meru Advisors can be contacted at lglaser@meruadvisors.com. They are ready to address any questions or provide insights into Avalo's initiatives.
Frequently Asked Questions
What are the main focuses of Avalo Therapeutics?
Avalo Therapeutics primarily concentrates on developing therapies for immune dysregulation and inflammatory diseases.
When will Avalo participate in the investor conferences?
Avalo Therapeutics will participate in the TD Cowen conference on March 3, 2025, and the Leerink Partners conference on March 12, 2025.
How can one access the conference presentations?
Live webcasts of the conference presentations will be available on the Avalo Therapeutics website under the "News / Events" section.
What is the significance of AVTX-009?
AVTX-009 is designed to neutralize IL-1?, a critical factor in inflammatory diseases, making it a target for therapeutic intervention.
Who can I contact for more information regarding Avalo Therapeutics?
For inquiries, Christopher Sullivan, CFO, can be reached at ir@avalotx.com, and Lauren Glaser from Meru Advisors at lglaser@meruadvisors.com.
